The study was probably motivated by this: https://www.ftc.gov/news-events/news/press-releases/2021/10/...

Note that the study was conducted by companies that are in the business of conducting paid clinical trial for supplements manufacturers, and both were paid by the makers of XClear, so the study should be taken with a heaping grain of salt....

Especially considering that there is no other research suggesting that either xylitol or grape fruit extract is protective against COVID. Both are antimicrobials (i.e., antibacterial) but COVID is a virus.

> Especially considering that there is no other research suggesting that either xylitol or grape fruit extract is protective against COVID. Both are antimicrobials (i.e., antibacterial) but COVID is a virus

There are pre-print studies suggesting antiviral activity.

https://www.biorxiv.org/content/10.1101/2020.08.19.225854v1....

https://www.biorxiv.org/content/10.1101/2020.11.23.394114v1....

No, that 1st study merely confirms what is already known: that carageen has antiviral properties.

And the second link is just a precursor to the original study to make it seem like it was conducted separately (the researchers are the same). Even so, they found a concentration of greater than 80% was required for Xlear to have any statistical antiviral effects.